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Aim: Transcutaneous carbon dioxide (PtCO2) monitoring offers a potentially non-invasive and
continuous means to determine the arterial carbon dioxide tension (PaCO2). ED studies of
agreement between PtCO2 and PaCO2 have had conflicting findings and have not been targeted
to subgroups with severe ventilatory disturbance such as those requiring non-invasive ventila-
tion [NIV]. Our aim is to determine agreement between PtCO2 and PaCO2 for patients under-
going NIV for respiratory failure.
Methods: This prospective observational study included a convenience sample of patients
undergoing NIV for respiratory failure who required arterial blood gas analysis as part of their
care. Data collected included patient demographics, indication for NIV, diagnosis, vital signs,
and pH, PaCO2 and PtCO2. The outcome of interest was agreement between PaCO2 and PtCO2.
Analysis was made using descriptive statistics, Bland-Altman techniques, ManneWhitney U test
and Fisher/Chi square tests.
Results: 46 comparisons were analysed. Median age was 69 [IQR 65e79], 67% male; median
PaCO2 60 mmHg [IQR 46e70] and median pH 7.35 [IQR 7.30e7.38]. Average difference between
PaCO2 and PtCO2 was 6.1 mmHg with 95% limits of agreement 10.1e22.3 mmHg. Thirty seven
comparisons [80%] were within 10 mmHg [95% CI 66e90%]. Difference >10 mmHg was associ-
ated with increasing PaCO2 [p Z 0.001; median difference 19.6 mmHg, 95% CI
9.2e30.4 mmHg]. All cases with difference >10 mmHg had PaCO2 > 60 mmHg.
Conclusion: In patients undergoing NIV, agreement between PaCO2 and PtCO2 was sub-optimal,
with unacceptably wide 95% limits of agreement. PtCO2 cannot be recommended as a substi-
tute for PaCO2 testing in this group.
ª 2010 Elsevier Ltd. All rights reserved.nshine Hospital, Furlong Road, St Albans 3021, Australia. Tel.: þ61 3 8345 6315.
wh.org.au (A.-M. Kelly).
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Table 1 Characteristics of sample.
Variable Data
Gender Male 29, 63%
Age [years] Median 69, IQR 65e79, range 48e88
Diagnosis COAD 31, 67%
CHF/APO 15, 33%
FiO2 Median 30%, IQR 30e40%, range 21e100%
Pulse rate
[bpm]
Median 97, IQR 87e104, range 53e230
Systolic blood
pressure
[mmHg]
Median 131, IQR 117e151, range 96e100
O2 saturation
[%]
Median 94, IQR 90e97, range 66e100
Capillary refill
time [secs]
Median 2, IQR 2e3, range 1e4.
[missing data 10]
PaC02 [mmHg] Median 60, IQR 46e70, range 33e91
pH Median 7.35, IQR 7.30e7.38,
range 7.22e7.45
Acidotic [pH <7.35], n Z 23, 50%
30
40
50
60
70
80
90
100
30 40 50 60 70 80 90 100
P
a
C
O
2
PtCO2
Scatter Plot
Figure 1 Scatter plot of agreement between PtCO2 and
PaCO2.
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Transcutaneous carbon dioxide (PtCO2) monitoring offers
a potentially non-invasive and continuous means to deter-
mine the arterial carbon dioxide tension (PaCO2). A number
of studies have reported good agreement between PtCO2
and PaCO2 values in surgical,
1,2 paediatric critical care3 and
cardiopulmonary exercise testing4 settings. ED studies have
had conflicting findings5e7 and have not been targeted to
subgroups with severe ventilatory disturbance such as those
requiring non-invasive ventilation [NIV]. Two small respi-
ratory unit studies have investigated agreement in patients
undergoing NIV. Storre at al studied 10 patients reported an
average difference of 4.6 mmHg with 95% limits of agree-
ment from 3.9e13.2 mmHg.8 Cox et al studied 22 patients
reporting an average difference of approximately
1.5 mmHg with 95% limits of agreement from 6.75 mmHg
to 4.5 mmHg. In addition, in laboratory tests, it has been
reported that changes in PtCO2 in response to acute
progressive changes in PaCO2 vary among subjects.
9
Our aim is to determine agreement between PtCO2 and
PaCO2 for patients undergoing NIV for respiratory failure in
an emergency department [ED]. We hypothesised that
PtCO2 would have acceptable agreement with PaCO2 [95%
limits of agreement less than 10 mmHg].
Methods
This prospective observational study including a conve-
nience sample of patients undergoing NIV for respiratory
failure [either chronic airways disease or acute pulmonary
oedema] who required arterial blood gas analysis as part of
their care. Patient management and NIV settings were at
the discretion of the treating physician.
Data collected included patient demographics, indication
for NIV, vital signs and PaCO2 and PtCO2. PtCO2wasmeasured
using a TCM4 series transcutaneous carbon dioxide monitor
[Radiometer Medical ApS, Denmark] and arterial blood gas
samples were analysed on a Radiopoint 405 [Siemens
Healthcare Diagnostics Inc. NY, USA]. Probes were placed on
the trunk, usually the upper chest, using the conductive
solution as per manufacturer’s instructions. Staff were
instructed to wait at least 5 min after applying the trans-
cutaneous sensor to allow equilibrium to be reached.
The primary outcome of interest was agreement between
PaCO2 and PtCO2. Analysis was made using descriptive
statistics, Bland-Altman techniques, ManneWhitney U test,
Fisher or Chi Square tests for comparison of proportions as
appropriate and Spearman correlation for the relationship
between CO2 difference and pH. The institutional ethics
panel waived requirement for patient consent.
Results
46 comparisons were analysed. Median age was 69 [IQR
65e79], 67% were male; median PaCO2 was 60 mmHg [IQR
46e70] and median pH was 7.35 [range 7.22e7.46, 23
patients acidotic] [Table 1]. A scatter plot of the relation-
ship between PaCO2 and PtCO2 is shown in Fig. 1.
Average difference between PaCO2 and PtCO2 was
6.1 mmHg with 95% limits of agreement 10.1e22.3 mmHg.[Fig. 2] Thirty seven comparisons [80%] were within
10 mmHg [95% CI 66e90%]. Difference >10 mmHg was
associated with increasing PaCO2 [p Z 0.001; median
difference 19.6 mmHg, 95% CI 9.2e30.4 mmHg], but not
with pulse rate [p Z 0.74], systolic blood pressure
[p Z 0.60], O2 saturation [p Z 0.10], capillary refill time
[pZ 0.55], diagnosis [pZ 0.75] or pH [pZ 0.39]. All cases
with difference >10 mmHg had PaCO2 > 60 mmHg. Corre-
lation between CO2 difference and pH was poor [r statistic
0.26, 95% CI 0.04e0.51].
Discussion
This study found an average difference between PaCO2 and
PtCO2 of 6.1 mmHg, however the 95% limits of agreement
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Figure 2 Bias plot of agreement between PtCO2 and PaCo2.
228 A.-M. Kelly, S. Klimwere wide [10.5e23.5 mmHg] with PaCO2 higher than
PtCO2. There was also significant between individual vari-
ation in the difference which could challenge clinical
utility. Agreement was worse at higher PaCO2.
Our findings are in contrast with previous ED studies.
Perrin et al., in a study of patients with asthma or pneu-
monia, reported an average difference of 0.13 mmHg with
95% limits of agreement 3.9e3.7 mmHg.5 It should be
noted that this study excluded patients with respiratory
failure which is the group targeted by our study. McVicar et
al reported an average difference of 1.5 mmHg with 95%
limits of agreement þ/ 6.75 mmHg.6 Our limits of
agreement are also wider than the previous study of
patients undergoing NIV.7,8 Reasons for these differences
might include the impact of acidosis of skin perfusion,
differences in monitors used, differences in severity of
illness and differences in staff training regarding device
use. This study is also larger and more heterogeneous that
the two previous studies of patients undergoing NIV so may
be more likely to identify outliers.
Our finding that agreement between PaCO2 and PtCO2 to
within 10 mmHg deteriorated at higher PaCO2 levels with
PtCO2 underestimating PaCO2 is important as the patient
group requiring NIV are likely to have high PaCO2 levels.
This was also evident in the data reported by Storre et al,8
but was not commented on by them. While the absolute
value of PaCO2 may have limited clinical value in isolation,
the median difference between PtCO2 and PaCO2 of
19 mmHg at PaCO2 levels >60 mmHg could falsely give the
impression of near-normal PaCO2 and adversely impact
clinical decision making. An awareness of this would be
necessary if PtCO2 was in routine use for this group of
patients.
For patients with respiratory failure requiring NIV, blood
gas analysis is not a one off test. While an initial blood gas is
usually obtained to measure PaCO2 and pH, repeated
analyses are usually required to assess progress. There is
good evidence that venous pH is clinically equivalent to
arterial pH.10 Used in combination with venous pH,
a potential role for PtCO2 is in monitoring progress partic-
ularly changes in PaCO2 over time. This is supported by the
findings of Storre et al who reported that PtCO2 trend
reliably reflected the trend of change in PaCO2 in patientsundergoing NIV.8 This was however a small study and
further corroboration would be desirable.
This study has some limitations that should be consid-
ered when interpreting the results. It is a single centre
study using a single monitor. The study included patients
with respiratory failure from both pulmonary oedema and
chronic airways disease. It is possible that there was
a difference in performance between these groups that
the subgroup sizes are not sufficient to detect. The
acceptable limits of agreement of þ/10 mmHg were
chosen arbitrarily, based on previous studies. A different
definition would change the proportion of comparisons
classified as acceptable. It is possible that patient factors
such as body habitus, fever and sweating impacted
monitor performance. We did not collect data regarding
these.
Conclusion
In the NIV group of patients, agreement between PaCO2 and
PtCO2 was sub-optimal, with wide 95% limits of agreement.
PtCO2 cannot be recommended as a substitute for PaCO2
testing in this group. It may however have a role in moni-
toring trend and effectiveness of treatment.Acknowledgement
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